In vitro protection of plasma cholinesterases by metoclopramide from inhibition by paraoxon

Journal of Applied Toxicology

Volumn 23, Issue 1, 2003, Pages 75-79

  Petroianu, G ^a   Kuhn F ^b   Thyes, C ^b   Ewald, V ^b   Missler, A ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cholinesterase; Metoclopramide; Organophosphate; Pralidoxime

Indexed keywords

ACETYLTHIOCHOLINE; BUTYRYLTHIOCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; METOCLOPRAMIDE; PARAOXON; SEROTONIN AGONIST;

ACCIDENT; CALCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; ENZYME SUBSTRATE; EXPOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; IC 50; IN VITRO STUDY; INTOXICATION; MALE; NORMAL HUMAN; PHOTOMETRY; PRIORITY JOURNAL; REVIEW; SUICIDE; VOLUNTEER;

CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; CHOLINESTERASES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METOCLOPRAMIDE; PARAOXON;

EID: 0037258618     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.891     Document Type: Review

References (22)

1. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R. 1996. Indirect Parasympathomimetic activity of Metoclopramide: Reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res. 34: 65-72.
2. Geldmacher-von Mallinkrodt M, Urbach HJ, Kittel H, Lindorf HH. 1969. Zur Messung der in vivo und in vitro Reaktivierbarkeit alkylphosphatvergifteter Serumcholinesterase durch 2-PAM und Toxogonin mit verschiedenen Substanzen. Z. Klin. Chem. Klin. Bioochem. 7: 480-485.
3. Graham SG, Crossley AWA. 1995. The characteristics of the inhibition of serum cholinesterase by metoclopramide. Eur. J. Clin. Pharmacol. 48: 25-228.
4. Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA, Marrs TC, Szinicz L, Vale JA, Haines JA. 2000. Evaluation of antidotes for poisoning by organophosphourus pesticides. Emerg. Med. 12: 22-37.
5. Karalliedde L. 1999. Organophosphourus poisoning and anaesthesia. Anaesthesia 54: 1073-1088.
6. Levine R. 1991. Recognized and possible effects of pesticides in humans. In Handbook of Pesticide Toxiclogy, General Principles Vol. 1, Hayes WJ, Laws ER (eds). Academic Press: San Diego; 275-360.
7. McGovern EM, Gravel J, Bryson SM. 1986. Pharmacokinetics of high-dose metoclopramide in cancer patients. Clin. Pharmacokin. 11: 415-424.
8. Namba T. 1971. Cholinesterase inhibition by organophospourus compounds, and its clinical effects. Bull. WHO 44: 289-307.
9. Namba T, Nolte CT, Jackrel J, Grob D. 1971. Poisoning due to organophosphate insecticides: acute and chronic manifestations. Am. J. Med. 50: 457-492.
10. Parfitt K. 1999. Martindale: The Complete Drug Reference (32nd edn). Pharmaceutical Press: Taunton, MA; 992-993.
11. Peter JV, Cherian AM. 2000. Organic insecticides. Anaesth. Intens. Care 28: 11-21.
12. Petroianu G, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 1998. Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs. J. Appl. Toxicol. 18: 293-298.
13. Petroianu G, Kärcher B, Kern N, Hardt F, Helfrich U, Rüfer R. 1999. L-Lactate reduces in vitro the inhibition of butyrylcholinesterase (BChE) by paraoxon (E600). J. Appl. Toxicol. 19: 329-336.
14. Petroianu G, Beha U, Roth C, Bergeler W, Rüfer R. 2000. L-Lactate protects in vitro acetylcholinesterase (AChE) from inhibition by paraoxon (E600). J. Appl. Toxicol. 20: 249-257.
15. Petroianu G, Hardt F, Toomes LM, Petroianu A, Bergeler W, Rüfer R. 2001a. High-dose i.v. paraoxon exposure does not cause organophosphate-induced delayed neuropathy (OPIDN) in mini pigs. J. Appl. Toxicol. 21: 263-268.
16. Ross-Lee LM, Eadie MJ, Hooper WD, Bochner F. 1981. Single-dose pharmacokinetics of metoclopramide. Eur. J. Clin. Pharmacol. 20: 465-471.
17. Roth J. 1991. Nerve gases. Dtsch. Apoth. Ztg. 131: 313-315.
18. Schmidt G, Zech R. 1988. Organophosphate. In Biochemie-Toxikologie-Therapie, Zivilschutzforschung, Bundesamt für Zivilschutz, Vol. 22. Osang: Bonn.
19. Sidell FR, Groff WA, Kaminskis A. 1972. Pralidoxime methane-sulfonate, plasma levels and pharmacokinetics after oral administration to man. J. Pharm. Sci. 61: 1136-1140.
20. Swartz RD, Sidell FR. 1973. Effects of heat and exercise on the elimination of pralidoxime in man. Clin. Pharmacol. Ther. 14: 83-89.
21. van Helden HP, Busker RW, Melchers BPC, Bruijnzeel PLB. 1996. Pharmacological effects of oximes: how relevant are they? Arch. Toxicol. 70: 779-786.
22. Zoch E. 1971. Die Wirkung organischer Phosphorsäureester bzw. Phosphorsäureester auf versch. Enzyme. Arzneim. Forsch. 21: 181-187.